NO980718L - Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer - Google Patents

Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer

Info

Publication number
NO980718L
NO980718L NO980718A NO980718A NO980718L NO 980718 L NO980718 L NO 980718L NO 980718 A NO980718 A NO 980718A NO 980718 A NO980718 A NO 980718A NO 980718 L NO980718 L NO 980718L
Authority
NO
Norway
Prior art keywords
alkyl
tyrosine kinase
kinase inhibitors
bicyclic
alkoxycarbonyl
Prior art date
Application number
NO980718A
Other languages
English (en)
Norwegian (no)
Other versions
NO980718D0 (no
Inventor
Maria Gabriella Brasca
Dario Ballinari
Antonio Longo
Franco Buzzetti
Original Assignee
Pharmacia & Upjohn Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa
Publication of NO980718D0 publication Critical patent/NO980718D0/no
Publication of NO980718L publication Critical patent/NO980718L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)
NO980718A 1996-06-21 1998-02-20 Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer NO980718L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9613021.6A GB9613021D0 (en) 1996-06-21 1996-06-21 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
PCT/EP1997/002965 WO1997049689A1 (en) 1996-06-21 1997-06-03 Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors

Publications (2)

Publication Number Publication Date
NO980718D0 NO980718D0 (no) 1998-02-20
NO980718L true NO980718L (no) 1998-04-08

Family

ID=10795666

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980718A NO980718L (no) 1996-06-21 1998-02-20 Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer

Country Status (20)

Country Link
US (1) US6057326A (de)
EP (1) EP0853616B1 (de)
JP (1) JPH11511761A (de)
KR (1) KR19990043993A (de)
CN (1) CN1198158A (de)
AR (1) AR008614A1 (de)
AT (1) ATE205836T1 (de)
AU (1) AU3094197A (de)
BR (1) BR9702328A (de)
CA (1) CA2228492C (de)
DE (1) DE69706823T2 (de)
EA (1) EA199800215A1 (de)
ES (1) ES2165061T3 (de)
GB (1) GB9613021D0 (de)
HU (1) HUP9902026A3 (de)
IL (1) IL123124A0 (de)
NO (1) NO980718L (de)
PL (1) PL325122A1 (de)
WO (1) WO1997049689A1 (de)
ZA (1) ZA975380B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6347480B1 (en) * 1997-07-07 2002-02-19 Southpac Trust International, Inc. Method for wrapping a floral grouping with a sheet of material constructed of paper and having printed and embossed patterns thereon
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6608060B1 (en) 1996-12-18 2003-08-19 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US5945418A (en) * 1996-12-18 1999-08-31 Vertex Pharmaceuticals Incorporated Inhibitors of p38
US6147080A (en) * 1996-12-18 2000-11-14 Vertex Pharmaceuticals Incorporated Inhibitors of p38
DE19653646A1 (de) * 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
PT1154774E (pt) * 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
SV2002000205A (es) * 1999-11-01 2002-06-07 Lilly Co Eli Compuestos farmaceuticos ref. x-01095
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
ES2267748T3 (es) 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.
US20040235867A1 (en) * 2001-07-24 2004-11-25 Bilodeau Mark T. Tyrosine kinase inhibitors
KR100468352B1 (ko) * 2002-09-24 2005-01-27 한국과학기술연구원 신규 피라졸로피리미딘계 유도체, 그의 제조방법 및 이를 유효성분으로 하는 약학적 조성물
MXPA06001758A (es) * 2003-08-15 2006-08-11 Irm Llc Anilino purinas sustituidas en la posicion 6 utiles como inhibidores de rtk.
EP2650286A1 (de) * 2004-02-19 2013-10-16 Rexahn Pharmaceuticals, Inc. Chinazolinderivate und therapeutische Verwendung davon
US7151176B2 (en) * 2004-10-21 2006-12-19 Bristol-Myers Squibb Company Pyrrolotriazine compounds
WO2006104971A1 (en) * 2005-03-28 2006-10-05 Bristol-Myers Squibb Company Atp competitive kinase inhibitors
US8507502B2 (en) 2008-11-10 2013-08-13 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
UA110113C2 (xx) * 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
EP3660016A1 (de) * 2010-12-20 2020-06-03 Incyte Holdings Corporation N-(1-(substituierte phenyl)ethyl)-9h-purin-6-amine als pi3k-hemmer
AU2020253561A1 (en) * 2019-04-03 2021-12-02 Mitokinin, Inc. Compositions and methods of using the same for treatment of neurodegenerative and mitochondrial disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89028A0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
ZA902280B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor agents
JP2762430B2 (ja) * 1991-01-18 1998-06-04 宇部興産株式会社 アラルキルアミノピリミジン類の製法
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH06172321A (ja) * 1992-10-08 1994-06-21 Agro Kanesho Co Ltd 置換アミノピリミジン誘導体、その製造法及びそれを有効成分とする有害生物駆除剤
GB9313638D0 (en) * 1993-07-01 1993-08-18 Erba Carlo Spa Arylidene and heteroarylidene oxindole derivatives and process for their preparation
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
GB9406137D0 (en) * 1994-03-28 1994-05-18 Erba Carlo Spa N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation
GB9412719D0 (en) * 1994-06-24 1994-08-17 Erba Carlo Spa Substituted azaindolylidene compounds and process for their preparation
GB9423997D0 (en) * 1994-11-28 1995-01-11 Erba Carlo Spa Substituted 3-arylidene-7-azaoxindole compounds and process for their preparation

Also Published As

Publication number Publication date
HUP9902026A2 (hu) 2000-04-28
CN1198158A (zh) 1998-11-04
GB9613021D0 (en) 1996-08-28
IL123124A0 (en) 1998-09-24
AR008614A1 (es) 2000-02-09
CA2228492A1 (en) 1997-12-31
US6057326A (en) 2000-05-02
ZA975380B (en) 1998-01-05
ES2165061T3 (es) 2002-03-01
BR9702328A (pt) 1999-07-20
KR19990043993A (ko) 1999-06-25
PL325122A1 (en) 1998-07-06
CA2228492C (en) 2007-05-08
DE69706823D1 (en) 2001-10-25
AU3094197A (en) 1998-01-14
WO1997049689A1 (en) 1997-12-31
JPH11511761A (ja) 1999-10-12
NO980718D0 (no) 1998-02-20
EA199800215A1 (ru) 1998-08-27
DE69706823T2 (de) 2002-04-11
MX9801408A (es) 1998-05-31
EP0853616A1 (de) 1998-07-22
EP0853616B1 (de) 2001-09-19
ATE205836T1 (de) 2001-10-15
HUP9902026A3 (en) 2000-07-28

Similar Documents

Publication Publication Date Title
NO980718L (no) Bicykliske 4-aralkylaminopyrimidinderivater og tyrosinkinaseinhibitorer
WO2001064643A3 (en) Benzamides and related inhibitors of factor xa
BG102637A (en) Tropane derivatives, their preparation and application
BG104248A (en) Benzamidoxim derivatives, intermediate products and methods for preparing and using them as fungicides
BR9610960A (pt) Derivados de 8-azabiciclo [3.2.1] oct -2- eno sua preparação e uso
NO986055D0 (no) Nye heterocykliske forbindelser, deres fremstilling, farmas÷ytiske preparat
DK0734389T3 (da) Rapamycinderivater, som er anvendelige som immunosuppressive midler
HRP20030943B1 (hr) Optičko razdvajanje (1-benzil-4-metilpiperidin-3-il)-metilamina i njegova upotreba u dobivanju pirolo 2,3-pirimidinskih derivata kao inhibitora protein kinaze
WO2004016597A3 (en) Protein kinase inhibitors and uses thereof
DK0765314T3 (da) Benzoheterocykliske derivater, der kan anvendes som vasopressin- eller oxytocinmodulatorer
NO306237B1 (no) Anvendelse av xantinderivater som antidepressive midler
NO973338L (no) N-(4-aryl-tiazol-2-yl)-sulfonamid-derivater og deres anvendelse
ZA202207667B (en) Sulfonimidamide compounds as nlrp3 modulators
WO2025054431A8 (en) Benzo-fused heterocyclic compounds and uses thereof
DK0733051T3 (da) Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister
WO2002026720A3 (en) PIPERAZINE BASED INHIBITORS OF FACTOR Xa
WO2005115984A3 (en) Large conductance calcium-activitated k channel opener
AU2896197A (en) Adenosine derivatives
MXPA04003278A (es) Derivados de 5-metoxi-8-aril-?1,2,4?triazolo?1,5-a?piridina como antagonistas del receptor de adenosina.
WO2002026718A3 (en) Bicyclic pyrimidin-4-one based inhibitors of factor xa
EA200001009A1 (ru) Производные пиридина, ингибирующие фосфодиэстеразу iv
CO4750824A1 (es) Nuevos intermedios y su uso para preparar bisindolilmaleimidas con un puente n,n
DE60206782D1 (de) Substituierte amide, sulfonamide und harnstoffe mit kinasehemmender wirkung
MX2007006919A (es) Formas cristalinas de un inhibidor del factor xa.
WO2002062801A1 (en) Triazoloquinazoline and pyrazolotriazolopyrimidine derivatives, medicinal compositions, adenosine a3 receptor affinity agents, ocular tension lowering agents, preparations for preventing and treating glaucoma and method of lowering ocular tension